Soleno Theraptcs Rg
SLNO
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
04/25/2026 - 02:00:00
Bid
04/27/2026 - 14:31:03
Bid
Volume
Ask
04/27/2026 - 14:31:03
Ask
Volume
52.72
-0.11 ( -0.21% )
52.17
200
57.61
100
More information
Analysis by TheScreener
24.04.2026
Evaluation Slightly negative  
Interest Strong  
Sensibility High  
Analysis date: 24.04.2026
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 06.01.2026.
Interest
  Strong
Three stars since 03.04.2026.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 06.01.2026 at a price of 46.14.
Evaluation
  Undervalued
 
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
  Positive
 
The dividend-adjusted forty day technical trend is positive since 03.04.2026.
4wk Rel Perf
  58.94%
 
The four-week dividend-adjusted overperformance versus SP500 is 58.94%.
Sensibility
  High
The stock has been on the high-sensitivity level since 15.07.2025.
Bear Market Factor
  Middle
On average, the stock is likely to decline with the index.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 5.50%.
Mkt Cap in $bn
  2.72
With a market capitalization between $2 & $8bn, SOLENO THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  1.69
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  6.14
The estimated PE is for the year 2028.
LT Growth
  10.37%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  116
For 1% of index variation, the stock varies on average by 1.16%.
Correlation
  0.21
Stock movements are strongly independent of index variations.
Value at Risk
  40.94
The value at risk is estimated at USD 40.94. The risk is therefore 77.65%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  15.07.2025